OpenLobby.EU
Explore

Aboca S.p.a. Società Agricola

Aboca

A worldview based on awareness of the close bond between human and environmental health drives Aboca towards seeking for health today without compromising health tomorrow.

Lobbying Activity

Meeting with Ondřej Knotek (Member of the European Parliament)

26 Jan 2026 · Health Policy and Medical Device Regulation

Meeting with Friedrich Pürner (Member of the European Parliament)

10 Dec 2025 · Medical devices

Meeting with Dolors Montserrat (Member of the European Parliament, Rapporteur)

14 Oct 2025 · Review of the EU General Pharmaceutical Legislation

Meeting with András Tivadar Kulja (Member of the European Parliament)

7 May 2025 · Medtech sector, MDR legislation

Meeting with Aurelijus Veryga (Member of the European Parliament)

8 Apr 2025 · Making EU rules work better for innovative medical devices

Meeting with Elena Nevado Del Campo (Member of the European Parliament)

7 Apr 2025 · Medical Devices

Meeting with Salvatore D'Acunto (Head of Unit Internal Market, Industry, Entrepreneurship and SMEs)

25 Mar 2025 · Single market issues regarding natural food supplements

Meeting with Antonella Sberna (Member of the European Parliament)

18 Feb 2025 · Innovazione terapeutica e dispositivi medici a base naturale, sostenibilità ambientale e sanitaria, regolamentazione europea, digitalizzazione e prevenzione nella medicina territoriale.

Meeting with Antonella Rossetti (Cabinet of Commissioner Christophe Hansen)

17 Feb 2025 · Introductory meeting - natural substances, rhubarb case, farmer support, organic sector

Meeting with Dario Nardella (Member of the European Parliament)

4 Feb 2025 · Priorities in the field of Agriculture and rural development

Meeting with Salvatore D'Acunto (Head of Unit Internal Market, Industry, Entrepreneurship and SMEs)

4 Feb 2025 · Single market issues regarding natural food supplements

Meeting with Annalisa Corrado (Member of the European Parliament)

2 Dec 2024 · Agriculture and sustainability

Meeting with Dario Nardella (Member of the European Parliament)

15 Oct 2024 · Priorities in the field of Agriculture and rural development

Meeting with Beatrice Covassi (Member of the European Parliament)

1 Aug 2023 · Health - Natural and biodegradable products

Meeting with Elisabetta De Blasis (Member of the European Parliament)

1 Jun 2023 · Presentation of the activities and collaboration with the enterprise

Meeting with Nicola Danti (Member of the European Parliament)

21 Mar 2023 · Presentazione attività azienda

Response to Sustainable use of pesticides – revision of the EU rules

29 Jul 2020

We welcome this initiative and thank the Commission to provide stakeholders with the opportunity to comment. Aboca is an Italian company founded 42 years ago in Sanselpocro, Tuscany. It is an agricultural company active in the production of health products, physiological and therapeutic solutions made with medicinal plants. Aboca cultivates directly about 1700 hectares between Tuscany and Umbria according to the organic farming scheme. In the enclosed document you will find some elements we deem important in order to develop an effective and signficant legislative framework that aims at reducing the use of pesticides and promote sustainable measures.
Read full response

Response to Initiative prohibiting and permitting under scrutiny certain hydroxyanthracene derivatives in food supplements

26 Mar 2020

Aboca is an Italian healthcare company based in Sansepolcro, province of Arezzo, Tuscany. Aboca was established 40 years ago with the aim of searching for human health solutions in natural substances, based on scientific evidence and developed according to the Systems Medicine and the Systems Biology approach. The company has more than 1500 and the products are sold in 16 Countries, in and outside Europe. In the enclosed letter, the founder and President of the Aboca Group explains why a ban of certain hydroxyanthracene derivatives would represent a step back in terms of scientific development, and why the HADs case should be seen in a broader context. If approved, the proposed regulation would lead to the loss of an important class of substances which benefit the health of European citizens, and it would also have a devastating impact on the entire food and pharmaceutical sector. We should look at the hydroxyanthracene derivatives case in a wider context and as an opportunity to change the approach and develop proper assessment criteria to exploit the potential of natural substances. Those substances offer us the possibility to find innovative and sustainable solutions for health. All this is in complete harmony with the principles that underlie the “Green New Deal” which considers the sustainability of our progress as pivotal in an evaluation of what is meant by “value” and “progress”. Thanks to the Systems Medicine and Systems Biology approach, we are now able to exploit the potential of the emerging properties of natural substances. To make this happen, the political vision needs to be supported by adequate investments in research and the establishment of dedicated EU programmes. Aforementioned comments are expanded and explained in the enclosed letter.
Read full response

Meeting with Marco Valletta (Cabinet of Commissioner Vytenis Andriukaitis)

10 Apr 2018 · CAP reform + Natura products